Abstract
Voriconazole is a broad-spectrum triazole antifungal agent and the first-choice therapy for invasive aspergillosis (IA) ([1][1]). Although voriconazole is generally well tolerated, anecdotal case reports have described unexpected severe adverse events related to voriconazole, such as hyponatremia,
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
